Nitric oxide-producing CD11b+Ly-6G(Gr-1)+CD31(ER-MP12)+ cells in the spleen of cyclophosphamide-treated mice: Implications for T-cell responses in immunosuppressed mice

Blood

Volumn 95, Issue 1, 2000, Pages 212-220

  Angulo, Iñigo ^b   Gómez De Las Heras, Federico ^b   García Bustos, José F ^b   Gargallo, Domingo ^b   Muñoz Fernández, M Angeles ^b   Fresno, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CYCLOPHOSPHAMIDE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; IMMUNE DEFICIENCY; LYMPHOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0343185921     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.1.212.001k27_212_220     Document Type: Article

References (60)

1. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92:1471-1490.
2. Parkman R, Weinberg KI. Immunological reconstitution following bone marrow transplantation. Immunol Rev. 1997;157:73-78.
3. Grochow LB. Covalent-DNA binding drugs. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins; 1996:293-316.
4. Botnick LE, Hannon EC, Hellman S. Limited proliferation of stem cells surviving alkylating agents. Nature. 1976;262:68-70.
5. Siena S, Castro-Malaspina H, Gulati SC, et al. Effects of in vitro purging with 4-hydroperoxycy-clophosphamide on the hematopoietic and microenvironmental elements of human bone marrow. Blood. 1985;65:655-662.
6. Braciale VL, Parish CR: Inhibition of in vitro antibody synthesis by cyclophosphamide-induced suppressor cells. Cell Immunol. 1980;51:1-12.
7. Segre M, Tomei E, Segre D. Cyclophosphamide-induced suppressor cells in mice: suppression of the antibody response in vitro and characterization of the effector cells. Cell Immunol. 1985;91: 443-454.
8. Shimizu M, Sabolovic D, Ozawa H, Iwaguchi T. Cyclophosphamide-induced suppressor cells in nude mice. Anticancer Drugs. 1992;3:427-433.
9. Nikcevich DA, Duffie GP, Young MR, Ellis NK, Kaufman GE, Wepsic HT. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57BL/6 mice. Cell Immunol. 1987;109:349-359.
10. Maier T, Holda JH, Claman HN. Murine natural suppressor cells in the newborn, in bone marrow, and after cyclophosphamide. Genetic variations and dependence on IFN-γ. J Immunol. 1989;143: 491-498.
11. Wang BS, Lumanglas AL, James JP, et al. Reconstitution of cytolytic alloreactivity with N-[4-[(4-fluorophenyl)sulfonyl]phenyl]acetamide (CL 259,763) in animals immunocompromised by cyclophosphamide. Int J Immunopharmacol. 1989; 11:479-486.
12. Brooks-Kaiser JC, Bourque LA, Hoskin DW. Heterogeneity ot splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharmacology. 1993;25:117-129.
13. Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci U S A. 1985; 82:7738-7742.
14. MacMicking J, Xie Q, Nathan C. Nitric oxide and macrophage function. Ann Rev Immunol. 1997; 15:323-350.
15. Griffith OW, Stuehr DJ. Nitric oxide synthases: properties and catalytic mechanism. Ann Rev Physiol. 1995;57:707-736.
16. Albina JE, Abate JA, Henry WL Jr. Nitric oxide production is required for murine resident peritoneal macrophages to suppress mitogen-stimulated T cell proliferation. J Immunol. 1991;147: 144-148.
17. al-Ramadi BK, Meissler JJ Jr, Huang D, Eisenstein TK. Immunosuppression induced by nitric oxide and its inhibition by interleukin-4. Eur J Immunol. 1992;22:2249-2254.
18. Schleifer KW, Mansfield JM. Suppressor macrophages in African trypanosomiasis inhibit T cell proliferative responses by nitric oxide and prostaglandins. J Immunol. 1993;151:5492-5503.
19. Hoffman RA, Langrerh JM, Wren SM, et al. Characterization of the immunosuppressive effects of nitric oxide in graft-versus-host disease. J Immunol. 1993;151:1508-1518.
20. Bocca AL, Hayashi EE, Pinheiro AG, et al. Treatment of Paracoccidioides brasiliensis-infected mice with a nitric oxide inhibitor prevents the failure of cell-mediated immune response. J Immunol. 1998;161:3056-3063.
21. Angulo I, Rodriguez R, García B, Medina M, Navarro J, Subiza JL. Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-γ. J Immunol. 1995;155: 15-26.
22. 15N]-nitrate in biological fluids. Anal Biochem. 1982;126:131-138.
23. Griffiths MJ, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol. 1993;110: 963-968.
24. 6-(1-iminoethyl)lysine: a selective inhibitor of nitric oxide synthase. J Med Chem. 1994;37:3886-3888.
25. 6-(1-iminoethyl)lysine. Biochemistry. 1998;37:4844-4852.
26. Billiau A. Interferon-γ: biology and role in pathogenesis. Adv Immunol. 1996;62:61-130.
27. Heath AW, Wu WW, Howard MC. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur J Immunol. 1994;24:1828-1834.
28. Kiniwa M, Yanagiara Y, Tasaka K. Regulation of in vivo expression of Fc receptors for IgE (Fc∈R) on murine lymphocytes. II. Induction of Fc∈R and its inhibition in mice immunized with antigen. Int Arch Allergy Appl Immunol. 1990;93:242-248.
29. Punjabi CJ, Laskin DL, Heck DE, Laskin JD. Production of nitric oxide by murine bone marrow cells: inverse correlation with cellular proliferation. J Immunol. 1992;149:2179-2184.
30. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-γ and tumor necrosis factor-á. J Clin Invest. 1995; 96:1085-1092.
31. Abrahamsohn IA, Coffman RL. Cytokine and nitric oxide regulation of the immunosuppression in Trypanosoma cruzi infection. J Immunol. 1995; 155:3955-3963.
32. Krenger W, Falzarano G, Delmonte J Jr. Snyder KM, Byon JC, Ferrara JL. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. Blood. 1996;88:1113-1121.
33. 2. J Immunol. 1994;153:1674-1684.
34. Young MR, Wright MA, Matthews JP, Malik I, Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-β and nitric oxide. J Immunol. 1996;156:1916-1922.
35. Laskin DL, Heck DE, Punjabi CJ, Laskin JD. Role of nitric oxide in hematosuppression and benzene-induced toxicity. Environ Health Perspect. 1996;104(suppl):1283-1287.
36. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/ STAT5 signaling pathway. J Immunol. 1998;160: 5729-5734.
37. RayChaudhury A, Frischer H, Malik AB. Inhibition of endothelial cell proliferation and bFGF-induced phenotypic modulation by nitric oxide. J Cell Biochem. 1996;63:125-134.
38. Stassi G, De Maria R, Trucco WR, Testi R, Galuzzo A, Giordano C, Trucco M. Nitric oxide primes pancreatic β cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med. 1997;186:1193-1200.
39. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol. 1993;150:5080-5085.
40. Fehsel K, Kroncke KD, Meyer KL, Huber H, Wahn V, Kolb-Bachofen V. Nitric oxide induces apoptosis in mouse thymocytes. J Immunol. 1995;155: 2858-2865.
41. Puddu P, Fantuzzi L, Borghi P, Varano B, Rainaldi G, Guillemard E, Malomi W, Nicaise P, Wolf SF, Belardelli F, Gessani S. IL-12 induces IFN-γ expression and secretion in mouse peritoneal macrophages. J Immunol. 1997;159:3490-3497.
42. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J Exp Med. 1998;187: 2103-2108.
43. Pimentel-Muiños FX, Muñoz-Fernández MA, Fresno M. Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. J Immunol. 1994;152:5714-5722.
44. Larsen CP, Alexander DZ, Hollenbaugh D, et al. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation. 1996;61:4-9.
45. Tian L, Noelle RJ, Lawrence DA. Activated T cells enhance nitric oxide production by murine splenic macrophages through gp39 and LFA-1. Eur J Immunol. 1995;25:306-309.
46. Bonham CA, Lu L, Li Y, Huffman RA, Simmons RL, Thomson AW. Nitric oxide production by bone marrow-derived dendritic cells: implications for the regulation of allogenic T cell responses. Transplantation. 1996;62:1871-1877.
47. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. R86-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993;151: 2399-2408.
48. de Bruijn MF, Slieker WAT, van der Loo JCM, Voerrnan JSA, van Ewijk W, Leenen PJM. Distinct mouse bone marrow macrophage precursors identified by differential expression of ER-MP12 and ER-MP20 antigens. Eur J Immunol. 1994;24: 2279-2284.
49. Ling V, Luxenberg D, Wang J, et al. Structural identification of the hematopoietic progenitor antigen ER-MP12 as the vascular endothelial adhesion molecule PECAM-1 (CD31). Eur J Immunol. 1997;27:509-514.
50. + hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factors. Blood. 1989;74:1905-1914.
51. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/granulocyle colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci U S A. 1997;94:1908-1913.
52. Ouaaz F. Nitric oxide in human hematopoiesis. Res Immunol. 1995;146:678-681.
53. + natural suppressor cells on IL-2 and IL-4 utilization in MLR. Transplantation. 1994;58:1096-1103.
54. Williams MS, Noguchi S, Henkart PA, Osawa Y. Nitric oxide synthase plays a signaling role in TcR-triggered apoptotic death. J Immunol. 1998; 161:6526-6531.
55. + cells. J Immunol. 1998;161:5313-5320.
56. Schwacha MG, Eisenstein TK. Interleukin-12 is critical for induction of nitric oxide-mediated immunosuppression following vaccination of mice with attenuated Salmonella typhimurium. Infect Immun. 1997;65:4897-4903.
57. Koblish HK, Hunter CA, Wysocka M, Trinchieri G, Lee WM. Immune suppression by recombinant interleukin (rlL)-12 involves interferon gamma induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rlL-12 vaccine adjuvant effect. J Exp Med. 1998;188:1603-1610.
58. Lasarte JJ, Corrales FJ, Casares N, et al. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol. 1999;162:5270-5277.
59. Martins GA, Cardoso MAG, Aliberti JCS, Silva JS. Nitric oxide-induced apoptotic cell death in the acute phase of Trypanosoma cruzi infection in mice. Immunol Lett. 1998;63:113-120.
60. Wu-Hsieh BA, Chen W, Lee H. Nitric oxide synthase expression in macrophages of Histoplasma capsulatum-infected mice is associated with splenocyte apoptosis and unresponsiveness. Infect Immun. 1998;66:5520-5526.